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Abstract 
Iron overloading is a serious medical problem for blood transfusion-dependent 
diseases such as sickle cell disease, β-Thalassemia Major, and Myelodysplastic 
syndromes which require chronic blood transfusions to treat their related sequelae. 
Alternative treatment options to iron chelation therapy are currently lacking. The goal of 
this study was to identify a mechanism in a mouse model with the unique ability to 
excrete excess iron through urine and can uncover a novel pharmaceutical target to 
treat iron overload. The flaky-skin anemia (fsn) mouse possesses a mutation in the Ttc7 
gene (tetratricopeptide repeat domain 7) and had been observed to excrete elevated 
iron levels in its urine. We hypothesized that the mutation in fsn results in decreased 
transferrin-bound iron reabsorption in the kidney, resulting in elevated iron excretion in 
the urine. While the mechanism of high iron excretion in fsn mice remains unknown, we 
have ruled out the possibility of transferrin-bound iron leak from the kidney. fsn kidney 
cells not only expressed TfR1 (transferrin receptor-1) on the surface, but were capable 
of endocytosing transferrin-bound iron. Additionally, Cubilin and Megalin, known 
transferrin receptors, mRNA levels were not significantly different between fsn and WT 
littermate kidneys. However, we have detected lower levels of Dmt1 mRNA in the fsn 
kidney. Further work should focus on DMT1 protein expression in the nephron and 
investigate whether DMT1 (divalent metal transporter-1) protein levels impact the 
pathogenesis observed in the fsn anemia mouse mutant.  
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Introduction 
Sickle cell disease, β-thalessemia major and myelodysplastic syndrome (MDS) 
patients can require chronic blood transfusions, which lead to iron overloading, iron 
tissue deposition, and organ failure. Iron chelation therapy is the only current treatment 
available to decrease body iron stores. Complications associated with intravenous 
chelation include gastrointestinal disturbances, rash, joint pain, neutro/leucopenia, 
elevated serum creatinine, and decreased quality-of-life. In addition, poor compliance 
with chelation drugs results in increased morbidity and worse outcomes in those with 
iron overload. It has been estimated that up to 1 out of 3 patients prescribed intravenous 
chelation are non-compliant [1]. Oral chelation alternatives have improved problems 
with compliance, yet tolerance to the drugs and side effects still exist. Additionally, oral 
formulations such as deferasirox and deferiprone are significantly more expensive than 
the older intravenous formulation, deferoxamine. The overall costs, adverse events, 
complications, and decreased quality-of-life a patient endures leads to a successful 
treatment rate estimated at 48.8% to 63.9% with Deferasirox [1]. Therefore, there is a 
critical need to identify alternative methods of decreasing body iron stores in transfusion 
dependent diseases that will lead to better patient outcomes, improved safety, and 
increased compliance.  
Iron transport and utilization is under control of many proteins expressed in 
intestine, liver, bone marrow, and other tissues. Iron transport is initiated in the intestinal 
lumen with the aid of apical membrane protein divalent metal transporter 1 (DMT1, gene 
symbol Slc11a2) and the ferrireductase Dcytb to move iron into enterocytes. The iron 
exporter ferroportin (FPN1, gene symbol, Slc40a1), in concert with the ferroxidase 
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hephaestin, transports iron across the basal membrane into the blood where it is bound 
by transferrin (Tf) for transport to tissues [2]. Once in circulation, transferrin-bound iron 
(Tf-Fe) can be utilized by many cell types expressing transferrin receptors. Transferrin 
receptor 1 (TfR1) is expressed on many types of human cells including basal cells of the 
epidermis, kidney tubular epithelium, islets of Langerhans,   ppfer cells, hepatocytes, 
and seminiferous tubules [3]. Tf-Fe enters these cells via clathrin-mediated endocytosis. 
Apical membrane receptors Megalin, Cubilin, and TfR1 have been reported to bind and 
internalize Tf-Fe [2]. Once internalized into endosomes and the clathrin coat is 
removed, the proteins DMT1, STEAP3 ferrireductase, and endosomal H+/ATPases 
enable iron to dissociate from Tf and exit the endosome through DMT1 associated 
transport [2]. The iron can then be utilized by mitochondria to make heme, be used as a 
cofactor for enzymes, or stored bound to ferritin. 
In the kidney, Tf-Fe is filtered in metabolically significant amounts and is normally 
reabsorbed in the proximal tubule [4]. Both Cubilin/Megalin and TfR1 have been 
observed to endocytose Tf-Fe at the proximal tubule in mice [5,6]. DMT1 has also been 
described to be present at the proximal tubule and thick ascending limb of rat and 
mouse nephron [7,8]. It is hypothesized that the proximal tubule compartment relies 
upon receptor-mediated endocytosis for Tf-Fe reabsorption while the later nephron 
relies upon DMT1 mediated iron reabsorption to capture non-protein bound iron [8,9]. 
Mouse models have played a critical role in understanding the mechanisms of 
iron transport and the flaky-skin anemia (gene symbol, fsn) mouse is one example. The 
fsn mouse suffers from a hereditary anemia in the homozygous condition and has the 
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unique ability to excrete increased levels of iron through its urine [10]. Beamer et al. 
demonstrated a 72-fold increase in the amount of radioactive iron (59Fe) in fsn urine 
compared to wild-type (WT) controls 24 hours after oral 59Fe administration [10]. The fsn 
locus has been mapped to Chromosome 17 and contains a mutation in the gene 
tetratricopeptide repeat domain 7 (gene symbol, Ttc7) which  encodes a TPR repeat 
domain-containing protein (TTC7) [10-12]. The mutant phenotype of fsn mice is caused 
by a 5.5 kb viral DNA ETn (early transposon) insertion which results in the addition of an 
in-frame exon into the final fsn Ttc7 mRNA [11]. Recent studies in yeast, humans, and 
cell lines suggest that TTC7a acts as a transport protein for phosphatidylinositol 4-
kinase III alpha (PI4 IIIα) to form a complex at the plasma membrane with a 
membrane-associated protein, Efr3b [13-16]. Avitzur et al. hypothesized that the lack of 
TTC7a mediated transport of PI4 IIIα to the plasma membrane resulted in decreased 
phosphatidylinositol 4-phosphate (PIP4) production in a human intestinal cell line 
(Henle-407) [15]. Numerous reports have described the importance of 
phosphoinositides and phosphotidylinositide kinases in the process of clathrin-mediated 
endocytosis [16-20].  However, the specific role of TTC7a and PI4 IIIα in iron 
metabolism in the kidney remains unclear.  
We hypothesized that fsn mice have the ability to excrete high levels of iron in 
their urine due to defects in transferrin receptor mediated endocytosis in the kidney. The 
fsn Ttc7 mutation, which results in an elongated TTC7 protein, may be unable to 
transport PI4 IIIα to the plasma membrane effectively [11]. As a result, PI4 IIIα cannot 
function properly at the plasma membrane to maintain PIP4 levels. Alterations in 
phosphoinositide pools can have detrimental effects on endocytosis and downstream 
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signaling. Our aim was to characterize adult fsn mouse for renal transferrin endocytosis 
using flow cytometry, renal iron transport gene expression utilizing quantitative real-time 
PCR, and urinary iron loss via a transferrin ELISA and non-heme iron assay. This study 
would further elucidate the relationship of TTC7a and PI4 IIIα in renal iron reabsorption 
of fsn anemia mouse mutant.  
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Methods 
Ethics Statement 
Animal care and procedures were in accordance with institutional guidelines. 
This study was conducted under approval of University of Missouri at Kansas City 
IACUC and IBC (Protocol # 1214).   
Mice 
BALB/cJ-+/fsn mice were originally obtained from The Jackson Laboratory (Bar 
Harbor, ME). BALB/cJ-fsn/fsn mice were produced by mating BALB/cJ-+/fsn carrier 
mice. PCR genotyping was done to confirm homozygosity for the fsn Ttc7 mutation 
using primers specific to the Etn and Ttc7 sequence. By weaning age (21 days), the fsn 
phenotype is obvious with patchy flaky skin, hunched posture, and runted stature. WT 
and fsn littermates were housed at the University of Missouri at Kansas City Laboratory 
Animal Research Core facility.  
High Iron Diet 
A high iron diet (2% wt/wt Carbonyl Iron supplemented in Harlen Teklad 2018 
Rodent Diet) was purchased from Harlen Teklad (Madison, WI). For high iron diet 
experiments,  fsn and WT littermates were fed the high iron diet starting at 5 weeks of 
age as previously described for 4 weeks [12]. 
Quantitative Real-Time PCR (qRT-PCR) 
WT and fsn kidneys were used to extract RNA using RNeasy Midi kit (Qiagen 
Inc., Valencia, CA) according to manufacturer’s protocol. Quality of RNA and 
concentration was measured using agarose gel electrophoresis and spectrophotometry 
(NanoDrop2000). cDNA was synthesized from 500ng kidney RNA samples using 
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qScript cDNA SuperMix (Quanta Biosciences, Gaithersburg, MD). qRT-PCR was 
performed using PerfeCta Sybr Green FastMix (Quanta Biosciences, Gaithersburg, MD) 
on CFX Connect® qRT-PCR system (Bio-Rad Laboratories, Hercules, CA). All analysis 
was done on duplicate samples using the ΔΔCt method [21]. Internal controls were 
used and HPRT was used as the housekeeping gene. qRT-PCR primers were designed 
through IdtDNA PrimerQuest. All primers were optimized to at least 97% efficiency 
using standard curves of serial dilutions of the qRT-PCR reactions. All primers and 
reaction conditions are compiled in Table 1.  
Gene Sequence 
Final 
Concentration (nM) 
Annealing Temperature 
(°C) 
Cubilin 
F- CAGTCCTGGCTCCTTGATAAC 
R- GGAAAGGACCATCTCGAATCTC 
 
100 60 
Dmt1 
F- GGGTTGGCAGTGTTTGATTG 
R- CTGGGCTGTTAGTCATCTGG 
 
300 60 
Fpn1 
F- CTGGATTGTTGTTGTGGCAG 
R- CCAGGATGTTGGTTAGCTGG 
300 60 
HPRT 
F-TGGTGGAGATGATCTCTCAACTTT 
R-CCAGTGTCAATTATATCTTCCACAA 
 
400 60 
Megalin 
F- CCTTGCACAGACACCGAATA 
R- CTCCACAGTCGTCCACATTATC 
 
100 60 
PIP5Kg 
F- GGAGTGCCCATCCTGTATTT 
R- TTCTGTGTCTTGTCGTCTTTCT 
 
100 60 
Steap3 
F- CTGCTCAGCTTCTTCTTCGC 
R- TGCTTCACAGCCAGATTGAC 
300 60 
TfR1 
F-GTCCAGTGTGGGAACAGGTC 
R-CAGTCCAGCTGGCAAAGATT 
300 60 
PI4KIIIa 
F- GCTGGGAACCAGACATCAA 
R- GATAACCTCGGACACACATCTC 
 
100 58 
PIP5Ka 
F- GGAGAAAGGCTCCTGCTTTAT 
R- GACCAGTGCTTTCCAAGAGT 
 
300 58 
Efr3b 
F- CACCTGTGGCAGTCTTCTATG 
R- GGCACCAACCACAGCTAATA 
 
300 58 
PIP5Kb 
F- CCTGAAAGGCTCCACATACAA 
R- CAGGAAGTCCAGGTCCTTAAAC 
300 56 
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Table 1. qRT-PCR primers and reaction conditions. 
Flow cytometry 
fsn and WT littermate kidneys were dissected and made into single cell 
suspensions by cutting into pieces followed by successive needle aspirations (16G-
20G) in ice-cold 1X RPMI-1640 (Cellgro, Mediatech Inc., Manassas, VA). The cell 
suspensions were washed with ice-cold 1X RPMI-1640 and resuspended in the 
corresponding cocktail of either pHrodo Red-Transferrin (pHrodo-Tf) (Life Technologies, 
Grand Island, NY) or Transferrin Receptor 1-FITC (TfR1-FITC) or Rat IgG2ak-FITC 
(isotype-FITC) (Affymetrix eBioscience, San Diego, CA) in FluoroBrite 1X DMEM (Life 
Technologies, Grand Island, NY) supplemented with 25mM HEPES and 1% bovine 
serum albumin. pHrodo-Tf labeled samples were incubated for 20 minutes at 37°C while 
the TfR1-FITC and isotype-FITC labeled samples were incubated on ice for 45 minutes. 
Samples were then washed with ice-cold FluoroBrite DMEM (25mM HEPES, 1% BSA). 
Samples were run on BD LSRII flow cytometer (KUMed Flow Core). All analysis was 
done using FlowJo software (Tree Star Inc., Ashland, OR) gating on live cells and 
excluding doublets. Gating was based on unstained and isotype controls.  
Western Blot of kidney samples and Antibodies 
fsn and WT littermate kidney was dissected after 4 weeks on a high iron diet. 
Half of the kidney was used for protein extraction and other half for mRNA extraction 
described above. NP-40 cell lysis buffer with protease and phosphatase inhibitors (100X 
Halt™ Protease & Phosphatase Inhibitor Cocktail, Sigma-Aldrich, St. Louis, MO) were 
used to extract whole protein from kidney samples. Quantification of protein levels was 
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done via the BCA Protein Assay kit (Pierce™ Thermo Scientific, Waltham, MA). 20ug of 
total protein was loaded per sample on 4-15% TGX mini Protean gels (Bio-Rad 
Laboratories, Hercules, CA) and subjected to SDS-PAGE. Immunoblotting was 
performed with the following antibodies: Rabbit α-Rab5 mAb, Rabbit α-Rab7 mAb, 
Rabbit α-Rab11 mAb (Cell Signaling Technology Inc., Danvers, MA), and rabbit mAb-
HRP β-Actin (Cell Signaling Technology Inc., Danvers, MA). Secondary antibody used 
was α-Rabbit-Horseradish Peroxidase (Cell Signaling Technology Inc., Danvers, MA). 
Results were visualized by chemiluminescence, exposure on radiographic film, and 
band intensity was measured with UVP imaging system (UVP, LLC, Upland, CA). 
Densitometry was calculated with VisionWorksLS Analysis Software (UVP, LLC, 
Upland, CA). Relative band intensity was calculated by dividing each sample’s band 
intensity by its β-Actin loading control band intensity. 
Transferrin ELISA and Iron Measurement in Urine Samples 
After 3 weeks on the high iron diet, urine was collected at least 2 times a day for 
7 days from fsn and WT littermates by manual collection. Urine was pooled for each 
mouse and transferrin was measured with a mouse transferrin ELISA kit according to 
manufacturer’s protocol (GenWay BioTech Inc., San Diego, CA). Urine creatinine was 
measured at Children’s Mercy Hospital  ansas City’s Clinical Chemistry and Toxicology 
Laboratory per manufacturer’s protocol (CREA Slides, VITROS Chemistry Products, 
Ortho-Clinical Diagnostics, Inc., Rochester, NY) and was used to standardize transferrin 
urine levels. Iron urine levels was measured as previously described in serum [12]. 
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Urine Electrophoresis 
10 ul undiluted urine samples collected from WT and fsn mice on a high iron diet, 
as described above, were loaded 1:1 with laemmeli buffer on 4-15% TGX mini Protean 
gels (Bio-Rad Laboratories, Hercules, CA) and subjected to SDS-PAGE. Samples 
collected from mice on a normal diet were pooled from several mice and 10 ul was 
loaded for fsn and WT as described above. Total protein was resolved with Bio-Safe 
Coomassie (Bio-Rad Laboratories, Hercules, CA) per manufacturer’s protocol. Image 
was taken on UVP imaging system (UVP, LLC, Upland, CA).  
Statistics 
Two-sided Student’s t-test was used to compare means assuming unequal 
variance. All bar graphs represent means with standard error of the mean (SEM) error 
bars. Statistical significance was set at p<0.05. 
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Results 
Iron transport gene expression  
In order to determine whether the fsn Ttc7 mutation has an effect on iron 
transport gene expression, qRT-PCR was performed in whole kidney mRNA samples 
from fsn/fsn (fsn, n=5) or wild-type (WT, n=3) littermates. Our results demonstrate that 
transferrin receptor 1 (TfR1) mRNA expression was increased 1.77 fold (p=0.02) in 
kidney from fsn mice when compared to WT littermates at 5 weeks of age (Figure 1). 
Also, divalent metal transporter 1 (Dmt1) mRNA expression was nearly 2 fold (p=0.003) 
lower in fsn kidney compared to WT littermates (Figure 1). No changes were observed 
in Ferroportin (Fpn1) and Six-transmembrane epithelial antigen of the prostate (Steap3) 
expression in fsn and WT kidney at 5 weeks of age (Figure 1). 
 
Figure 1. Transferrin receptor 1 (TfR1) and Dmt1 mRNAs are differentially expressed in fsn kidney. 
mRNA from fsn/fsn (fsn) or wild-type (WT) littermates was used to measure gene expression in whole 
kidney. Black (fsn) and grey (WT) bars represent mean relative mRNA expression +/- SEM error bars. 
Statistical significance indicated by * = p<0.05, ** = p<0.01. 
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Transferrin receptor 1 & Transferrin uptake flow cytometry 
 Given the increased mRNA levels of TfR1, we sought to determine the surface 
protein expression of TfR1 in single cell suspensions of whole kidney from fsn (n=5) and 
WT (n=6) littermates. Our results show 15.6% of TfR1 positive kidney cells in fsn 
(p<0.01) versus 4.41% TfR1 positive in WT or heterozygous littermates (Figure 2a & 
2b). This data corroborates with the increase in the TfR1 expression observed in fsn 
kidney (Figure 1).  
 
Figure 2.  No defect in fsn kidney cells to express surface Transferrin receptor 1 (TfR1) or 
endocytose pHrodo-Tf iron. Single cell kidney suspensions from fsn/fsn (fsn) or wild-type (WT) 
littermates were used to measure the (A & B) percentage of TfR1+ cells (n=5, n=6) and (C) pHrodo-Tf 
uptake in vitro (n=3, n=3). Black (fsn) and grey (WT) bars represent (B) mean % TfR1+ or (C) mean % 
pHrodo-Tf+. Statistical significance indicated by * = p<0.05, ** = p<0.01. 
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The increased level of TfR1 mRNA and the increased population of TfR1-positive 
cells is fsn mice led us to determine whether transferrin receptor-mediated endocytosis 
was impaired in fsn kidney cells.  The ability of fsn and WT kidney cells to endocytose 
pHrodo Red-Transferrin (pHrodo-Tf), a pH-sensitive fluorescent dye bound to human 
transferrin, was measured. Surprisingly, the fsn kidney cells (n=3) showed 8.24% 
pHrodo-Tf positive cells compared to 5.01% pHrodo-Tf positive cells in WT (n=3) 
samples (p=0.027, Figure 2c).  These data suggest there is no defect in fsn kidney cells 
to internalize Tf-Fe when compared to WT mouse kidney cells. Given the pHrodo-Tf 
requires an acidic environment to fluoresce at maximal intensity; the fsn mice do not 
display an obvious defect in acidification of endosomal compartments with this assay.  
Endosomal protein markers in the kidney 
Tf and TfR1 are processed through endosomes and recycled to the plasma 
membrane. To determine if endosomal trafficking in fsn kidney cells was intact, the 
protein levels of known endosomal proteins were measured. Kidneys were dissected 
from fsn (n=3) and WT (n=2) mice placed on a high iron diet (2% wt/wt) and used for 
protein extraction. No difference in endosomal Rab5 and Rab11 protein levels was 
observed between fsn and WT kidney protein lysates (Figure 3b). However, Rab5 
protein levels had a trend of being higher in fsn samples compared to WT, p=0.08 
(Figure 3b). The endosomal Rab7 protein level was 20%  lower in fsn kidney samples at 
9 weeks of age compared to WT, p=0.007 (Figure 3b).  
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Figure 3. Rab7 protein, a late endosomal marker, is lower in fsn kidney samples. Kidney protein 
lysates were resolved via SDS-PAGE and immunoblotting from 9 week old fsn and WT mice on a high 
iron diet for 4 weeks. B.) Bar graphs represent mean relative band intensity for fsn (black, n=3) and WT 
(grey, n=2) +/- SEM error bars. Statistical significance indicated by * = p<0.05, ** = p<0.01. 
 
 
qRT-PCR on TTC7a and Transferrin endocytosis related genes 
 To determine the relative gene expression of the recently identified protein 
partners of TTC7a and transferrin endocytosis genes [4-6,14,15], quantitative real-time 
PCR (qRT-PCR) was utilized. Our results demonstrate that Megalin and Cubilin mRNA 
levels had a trend of being lower in fsn kidney when compared to WT, however, they 
were not statistically significant differences (Figure 4). Phosphatidylinositol 5-phosphate 
Kinase (PIP5K) isoforms and EfR3b did not show any significant differences between 
fsn and WT kidney samples (Figure 4). Interestingly, phosphatidylinositol 4-kinase III 
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alpha (PI4 IIIα) expression was decreased 36% in the fsn samples (n=5) compared to 
WT (n=3) samples (p=0.027, Figure 4). This data corroborates recent data 
demonstrating decreased PI4 IIIα protein by western blot in the human Henle-407 
intestinal cell line lentivirally infected with TTC7a shRNAs [15]. 
 
Figure 4. PI4KIIIα mRNA levels are decreased in fsn kidney. mRNA from fsn/fsn (fsn) or wild-type 
(WT) littermates was used to measure gene expression in whole kidney. Black (fsn) and grey (WT) bars 
represent mean relative expression +/- SEM error bars. Statistical significance indicated by * = p<0.05. 
 
Urinary transferrin detection and Urinary Iron levels 
 In order to determine if the urinary iron loss observed in fsn mice was related to 
transferrin bound iron excretion, we utilized a transferrin ELISA to measure urinary 
transferrin concentration. If our pHrodo-Tf assay is not sensitive enough to detect a 
defect in Tf-Fe uptake, the fsn urine samples should still contain higher levels of 
transferrin by this assay. WT (n=3) and fsn (n=3) mice were fed a high iron diet for 3 
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weeks and urine was collected daily for 7 days. Urine transferrin levels, as well as, urine 
non-heme iron levels were measured.  
 
Figure 5. No difference in urine transferrin levels between fsn and WT mice. A.) Urine was collected 
from fsn/fsn (fsn) and WT mice for 7 days after 3 weeks on a high iron diet. Black (fsn) and grey (WT) 
bars represent mean ng of transferrin per ug creatinine +/- SEM error bars. B.) Urine total protein 
resolved with Coomassie stain.10ul of urine loaded per sample onto Tris-Glycine SDS-PAGE gel. 10ug of 
mouse apo-transferrin and bovine serum albumin loaded as control samples. The fsn and WT samples on 
normal diet (no bar) were pooled from several mice at 5 weeks of age. 
Our results indicate that fsn mice do not have a significantly higher level of 
transferrin in their urine when compared to WT littermates (p=0.35, Figure 5A). 
Additionally, the mean iron concentration detected in fsn (n=2) samples was 36.5 µg/dl 
while the WT (n=3) urine samples were below the level of detection for the assay (<10  
µg/dl). It was further determined via urine electrophoresis that there was no gross 
proteinuria in the fsn urine samples versus WT (Figure 5B). However, some differential 
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banding was noted between WT and fsn samples on the high iron diet, as well as, 
between the normal diet and high iron diet urine samples.  These data suggest that the 
acute urinary iron loss observed in fsn mice is not due solely to transferrin-bound iron 
excretion.  
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Discussion 
 The current treatment for many blood transfusion-dependent patients 
experiencing iron overload is chelation. Intravenous chelation drugs have been the 
standard of care for reducing body iron stores. However, this approach has adverse 
effects including liver, kidney, visual and auditory toxicity, joint pain, and even death. 
Not every individual requiring chelation can tolerate treatment and there is currently a 
lack of alternative pharmaceuticals. The fsn mouse suffers from an iron deficiency 
anemia that is believed to be the result of defective iron metabolism [10-12]. Over 6 
weeks of life the serum iron levels decline in fsn mice compared to WT littermates 
whom accrue iron in the serum [12]. Additionally, it has been observed that fsn mice 
excrete high levels of iron in their urine after oral 59Fe administration compared to WT 
mice [10]. We set out to identify the mechanism by which fsn mice are able to excrete 
elevated iron in their urine. Further characterizing the defect in fsn mouse kidney could 
lead to the identification of pharmaceutical targets that modulate body iron storage, 
treating iron overload disorders. 
 Experiments were designed to identify whether known iron metabolism and 
transport genes were differentially expressed in fsn kidney compared to wild-type (WT). 
We found that Steap3, a ferrireductase, and Fpn1 mRNA expression was not different 
between fsn and WT kidney samples at 5 weeks of age (Figure 1). Interestingly, our 
data demonstrates that TfR1 and Dmt1 mRNA expression was differentially expressed 
in fsn mouse kidney samples at 5 weeks of age (Figure 1). TfR1 mRNA levels were 
1.77 fold higher while Dmt1 mRNA was nearly 2 fold lower in fsn samples when 
compared to WT (Figure 1). Further, our goal was to determine if this increase in TfR1 
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mRNA would translate into increased TfR1 protein levels in the kidney of fsn mice. Our 
data exhibited a 3.5 fold higher percentage of TfR1 positive cells in fsn kidney by flow 
cytometry compared to WT (Figure 2a, 2b).  
In order to identify if the observed TfR1 gene and protein expression increase 
was in compensation for a defect in TfR1 endocytosis, we aimed to verify whether 
single cell suspensions of fsn kidney cells were capable of endocytosing a pH-sensitive 
dye labeled transferrin (pHrodo-Tf) molecule (Figure 2c). This assay is based on the 
principle that the pHrodo-Tf bound by TfR1 is internalized through clathrin-mediated 
endocytosis (Life Technologies, Grand Island, NY). Upon internalization and 
acidification of the endosome the pHrodo-Tf molecule fluoresces, allowing detection via 
flow cytometry. We observed that fsn kidney cells are capable of endocytosing pHrodo-
Tf (Figure 2c). This suggests that the TfR1 protein expression increase is not a result of 
a defect of TfR1 internalization and endosomal acidification. We speculated that the 
increased TfR1 mRNA and percent TfR1-positive cells in fsn kidney was related to the 
low iron status of these mice. TfR1 mRNA is known to contain iron response elements 
(IRE) which result in protection of the mRNA from degradation during low cellular iron 
levels [22-26]. However, the increased TfR1 mRNA and protein we observed suggested 
a compensatory effect as a result of a defect in downstream TfR1 endosomal trafficking 
and recycling.  
We measured the amount of endosomal Rab small GTPases by western blot in 
fsn and WT kidney to detect any difference in protein levels which could indicate 
endosomal trafficking dysfunction. Rab5, Rab7, and Rab11 are associated with 
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early/sorting, late, and recycling endosomes, respectively [27]. Our data showed that 
Rab5 and Rab11 protein levels were not statistically different in fsn kidney protein 
samples when compared to WT kidneys at 9 weeks of age though Rab5 protein had a 
trend of being higher in fsn kidney (Figure 3b). However, Rab7 protein levels were 
found to be 20% lower in the fsn kidney (Figure 3b).  This suggests that there may be a 
defect in the processing of late endosomes or the transition from early endosomes. 
Rab7 has classically been described as a late endosomal marker, however, recently it 
was shown to be required for early endosomal maturation events of low density 
lipoproteins [28]. siRab7 depletion led to a modest reduction in surface transferrin 
receptor or transferrin surface binding in Hela cells [28]. Girard et al. concluded that 
Rab7 in Hela cells had little impact on transferrin receptor recycling [28]. This is contrary 
to our results showing an increased percentage of surface transferrin receptor positive 
cells and modest increase internalization of fluorescent transferrin in fsn kidney cells 
(Figure 2). The observed differences could be species specific as Girard et al. utilized a 
Hela cell line. However, we speculated that the decreased Rab7 protein level in fsn 
kidney is not responsible for the increased urinary iron excretion in fsn mice.  
 In order to rule out changes in gene expression of other known transferrin 
binding proteins in the kidney, qRT-PCR was utilized. Cubilin and Megalin are known to 
work in concert to bind and internalize many proteins filtered by the glomerulus 
including IgA, intrinsic factor, albumin and transferrin [5,6,29-31]. However, our data did 
not detect a statistically significant difference in Cubilin or Megalin mRNA (Figure 4). 
Furthermore, our study assessed whether PIP5K mRNA levels, which are downstream 
of PI4 IIIα in the phosphotidylinositide cascade, were elevated to determine if a defect 
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in TTC7 (which is reported to affect PI4 IIIα localization) would result in PIP5K gene 
compensation. Our data did not demonstrate a difference in any of the three PIP5K 
isoform’s mRNA comparing fsn and WT 5 week old kidney samples indicating fsn 
kidney cells are not compensating with PIP5K gene expression (Figure 4). It was found; 
however, that PI4 IIIα mRNA levels were significantly lower in fsn samples (Figure 4). 
This corroborates a previous report demonstrating lower PI4KIIIα protein levels in 
human Henle-407 intestinal cells treated with lentiviral Ttc7a-shRNA particles [15]. 
Decreased PI4 IIIα at the membrane of fsn kidney cells could impact the ability to 
signal through PIP2 via secondary messengers diacylglycerol (DAG) and Ins(1,4,5)P3. 
As Bojjireddy et al. demonstrated after chemical inhibition of PI4 IIIα, strong 
phospholipase C stimulation led to PIP2 depletion in HEK293 cells [32].  
 We aimed to determine if the excess iron loss previously reported in the urine of 
fsn mice could be explained by urinary loss of transferrin bound iron [10]. Our data 
showed no difference in transferrin levels in the urine of fsn mice when compared to WT 
littermates though there was wide variability in the fsn samples (Figure 5a). This 
suggests that the excess iron excretion found in fsn urine in this study is not due to 
excess transferrin-bound iron loss. This also supports our observation that there is no 
defect in surface transferrin receptor expression or ability to internalize transferrin-
bound iron in the fsn kidney (Figure 2). Additionally, our data suggests no difference in 
mRNA levels of the known transferrin binding receptors Cubilin or Megalin in the fsn 
kidney (Figure 4). Urine electrophoresis of fsn and WT samples placed on a normal diet 
or high iron diet did resolve differential protein patterns.  
 
21 
 
These results suggest that the fsn kidney is capable of endocytosing transferrin-
bound iron and the previously reported acute urinary iron loss is not due to gross 
transferrin-bound iron excretion. The possibility cannot be ruled out that iron is being 
filtered through the glomerulus bound to other protein partners (ferritin, albumin, 
lipocalin etc.) or as free iron (Fe2+ or Fe3+). We suggest further investigation into the 
protein levels of DMT1 in the kidney of fsn mice. A deficiency of this critical iron 
transport protein could explain the urinary iron loss observed in fsn urine. It is important 
to note that known mouse and rat models containing mutated Dmt1 genes have been 
reported to excrete high levels of iron and transferrin in urine [7,33]. However, the 
Belgrade rat exhibits a renal developmental abnormality with lower glomeruli number 
compared to WT rats [7]. This is hypothesized to result in the observed progressive 
renal fibrosis and sclerosis. fsn mice could possess a condition in which there is a 
decrease in DMT1 protein that results in urinary iron loss without renal developmental 
issues. fsn mice have not been reported to have developmental kidney issues yet have 
been reported to have glomerular thickening and immune complex deposition in the 
mesangium as early as 4 weeks old [34]. 
Conclusions 
We have demonstrated that the fsn mouse kidney is not defective in internalizing 
transferrin-bound iron and urinary iron excretion cannot be explained by transferrin-
bound iron leak.  Further work should aim to identify the role of DMT1 protein in iron 
absorption in the nephron of fsn mice. We have demonstrated a lower Dmt1 mRNA 
level and this could reflect a decrease of apical DMT1 responsible for renal iron 
reabsorption.  
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